Format

Send to

Choose Destination
Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304. doi: 10.4168/aair.2016.8.4.298.

Update on the Management of Aspirin-Exacerbated Respiratory Disease.

Author information

1
Department of Medicine, Harvard Medical School, Boston, MA, USA.
2
Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA. kbuchheit@partners.org.
3
Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA.

Abstract

Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors. Management includes guideline-based treatment of asthma and sinus disease, avoidance of COX-1 inhibitors, and for some patients aspirin desensitization followed by high-dose aspirin therapy. Despite this, many patients have inadequately controlled symptoms and require multiple sinus surgeries. In this review, we discuss the current standard approaches to the management of AERD, and we introduce several therapeutics under development that may hold promise for the treatment of AERD.

KEYWORDS:

Aspirin-exacerbated respiratory disease; Samter's triad; aspirin desensitization; nasal polyps

Supplemental Content

Full text links

Icon for The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease Icon for PubMed Central
Loading ...
Support Center